-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FxeIF5agPZQ6Enew6bYdgacI2E0xgMNU5BQq5EY6wYDWJzTK3Iv7ZaqTjzsKF0lI 1PCJ3rsNvsdRNvMg2N+xCA== 0000950103-07-000874.txt : 20070405 0000950103-07-000874.hdr.sgml : 20070405 20070405133718 ACCESSION NUMBER: 0000950103-07-000874 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20070404 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070405 DATE AS OF CHANGE: 20070405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 07751369 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp05247e_8k.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 4, 2007

Shire plc
(Exact name of registrant as specified in its charter)

England and Wales
 (State or other jurisdiction of incorporation)

0-29630
98-0484822
(Commission File Number)
(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
 (Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               44 1256 894 000


 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))
 
 
 
Item 8.01. Other Events

Shire plc has issued the press releases attached as Exhibit 99.01, Exhibit 99.02, Exhibit 99.03, Exhibit 99.04 and Exhibit 99.05 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

99.01  Press Release dated April 4, 2007
99.02  Press Release dated April 4, 2007
99.03  Press Release dated April 4, 2007
99.04  Press Release dated April 5, 2007
99.05  Press Release dated April 5, 2007


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
SHIRE PLC
  
       
       
 
By:
/s/ A C Russell
  
   
Name: Angus Russell
  
   
Title: Chief Financial Officer
  
       
 
Dated: April 5, 2007
 
 
EXHIBIT INDEX
 
Number
  
Description
 
99.01
99.02
99.03
99.04
99.05
  
Press Release dated April 4, 2007
Press Release dated April 4, 2007
Press Release dated April 4, 2007
Press Release dated April 5, 2007
Press Release dated April 5, 2007
 
 
 
 
 EX-99.1 2 dp05247e_ex9901.htm Unassociated Document

EXHIBIT 99.01
 
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
       
 
Press Release
    

4 April 2007


Shire plc (the “Company”)

The trustee of the Shire plc Employee Benefit Trust (the “Trust”) notified the Company on 3 April 2007 that, on that day it exercised its discretion and released a total of 485 ordinary shares in the Company for nil consideration, being the release of shares to beneficiaries of the Trust in satisfaction of awards under the Shire Portfolio Share Plan.

None of the shares released were in respect of an award made to a director of the Company.

Following these transactions the trustee holds a total of 5,995,691 ordinary shares in the Company. The executive directors of the Company are amongst the potential beneficiaries under the Trust and are therefore regarded for Companies Act purposes as being interested in the shares held in them pursuant to DR 3.1.4R(1)(6).


Tatjana May
Company Secretary

 
 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
 
 
 
 
 
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
 

Registered in England 2883758 Registered Office as above
 
 
 GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#D`K`,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/W\H`*`"@`H`AGN+>TB::YGAMH8P2TL\B0QH`,DL[D!1CWI MI.]HIW[)?H@V\K?(^;]?_;"_9L\-7=S8:C\6O"LEW:,\=Q!IMZ-4>&1"0\3C M3Q+B0$$;>N01U%>Y2X9SRK&,HY=5C&6W.N3Y^];3_-=SFGB\-3WJQ6K6CZK? M;MU,F3]MO]E^*UENC\6?#^V%=QMXSL#_SQL4A,TO?[B&M(\*Y]S**RZHO M-V4?G*_*OO%]/A5\1O#&I^+_#'BVP;1-"N8++7IM3$ MNBSZ%>71B%M;:Q::FD$VG2RM/$(Q,B;RXVYS7D8O)LRP->EA:^%E&M73=-0M M-5$M^24+J5NO*W;J:TZU*I%RA)"))RTDTDKJJJH))8`"I((/B#3`00<$$?:.N:]!91F?3+Z]O^O4^OR(52FTFIQL]M4=OINI:?JUC; M:EI5[;:AIUW&)K2]LIH[BUN(B2!)!-$Q21,@C*DC@UQ3ISHSE3J0=.<'9QDK M.+[-/8M-6TV+M0`4`%`!0`4`%`!0`4`%`!0!B>)?$.E^$?#NN^*-7$D;SW-_.+*V:5O+\L$O)^U9;D^4\-X:-6JX M>WM"-3$35W*;;M&C%IN-WI&,%[2?6^R^=JU\1C)NG235.^R6B7=NVBMO?S[V M,'PO^RAX[U[2O[1\'^%M;^+$QMIHC<^#A%8^`M-U6*4PRV3>-M5,%OXINK1U M(G@T-)K4D@)J>X,HZ:^>X'#5'3Q>(IX!IWY:S;KN&C4G0A>5)36WM6JBOK25 MKD4\&Y*7(G5>OO134+M_S67-:VO+>_,K.R;/)/B/\"_C!\+XEU'Q]\-_$7A/ M3)9TM8M0N--G_L3[1(KO':1:K&TUL\Y5)"$-PSD*3R!7;A,UR['/EP>,I5Y1 M7PPE'G275PTE;7=HYZN'KT=9TG!;7M:/EJM-OF^NMSTS]FC]J_X@?L]>);`0 M:C?:W\/;F[@7Q%X,O+AY[7["7*SW>@B9C_9.J1)))*@A,<4[J%G5LAX^#/,@ MPF<8>490C1QD8OV59*TD]TIVMS0>SO=Q3O&VQMA<95P\HJ]Z2T<6[*W==FKW M\]GTM^K?[7GASPA=_LY?'CXO^#%TY]'^*/@'X(3)?Z6BP6VOG3?B2FHVVMW5 MLL2;[R32]?TN(3R`2E(!'(,P@#X'AO$8JGG64Y7B>95,NKX_W9.[I\^$<7"+ MN_=4JMC5'ZK7JT](U(4K-:7M4O>WI):]3\5_P!GI%'Q[^">%48^ M+'P\Q\H&,>+=)]J_2LZ;_L?-M7_N>*_&A,\3#-_6,.KNWM(=?[R/ZQZ_GT^M M"@""Z4M;7"J"S-!*JJ!DDF-@``.I)JH_%'U7Y@?RM7/[+_[0[7-PR?`SXHE& MGF92/`GB(`@R,01_Q+NA'/O7[_\`V[E'_0WPG_A32Z_]OGR7U;%1]WV%16Z* M,K?@K']$?[)?A_6_"G[./PD\/>(](U'0-] MSZ;#)QH4DXN#4=4U9KY.UCZ)KPS<*`"@`H`*`"@`H`*`"@#S/XK_`!>\`?!3 MPG=>,?B%KMOHFEP^9%9P',VI:SJ"PR31:5HUA'^\O;^41G``6.,9DGDBA1Y$ M[\NRS&9IB(X7!474GHY/:%.+=G*:<15 MVZJ_,GXH?'_4/%6D2>`/AUX>T[X4_"2TEV:?X/\.;H]4UN"*+RH;K MX@>)O^/SQAJ+R--.1=LUO&TX"Q.T"2G[C`Y5##U(XK&UI8_,-.:M4^&GWCAZ M2:A0A:R]VTY6;CLUS:[W[?T;_`CXA? M"_QW\._"_P#PJ[7-#OM(T?P]HEB^BZ7QIZ?\`E8\!937WYH1\M=/+9_F_5GVK\9_A M_P"*?A7_`,$V]=^'OC.ZTV\\1^%-$\.:;>SZ/UHV5$O`>O:IX2^$_A MB#X@WVERFTN?%=_JNQ039B:=9;&%V1FMY9XBLK?G MF4\#5\31AB,RKRP49J\:,(*55)[.;;4:;>_+:A[6(S.G1;A2CSN+U? MV5HGI;?>VZL[O72_@'A/_@JU\1+34(_^$W^&/@[6-*)<2)X8O]8\.:C"&"A' MCDU.?689]AW$QF.+?D`.G6O8Q'`&`<7]5QM:A/2WM(PJQ\[J/LFK]+/3?4YH MYO.ZYJ*M?HVG9W_%:>MGM?3]8/@E\=O`WQY\!1>._`]Q/Y,1>UUK0[\10ZSX M=U:*%9Y=*U2*&22,2^4\38SZIB4O>UIU(W]G M5@W;GA=)VO=232<6FFCUZ%:%:G&I#1=5UB^J_P"&T/SJE_X*R:1%+)$?@=J) M,?"'X,?%>3X9WFJ1?%^TUJ[@T-/%<-E)H`T9K-6274&\/ MS#43*;L8*V]OMV'AL\>3A.$98G,LTRY8]4_[,=-.?L6_:>T3?P^U7+:W\TKG M76QJHT:55T]*G12M;KV_RMYE#]G_`/X*"^'?C;XWU+PI?^`6^'^FZ/X.\0^, M]2\3:IXQMM0L;+3O#IL&O3V]AJ*0M)$+C3O#5B+:[%I*P26. M6[OK:4H<26L;'Y?4R[@&\(SS/%RI2:3]C04;QO9VE5ES1O:Z:C!I/:3.>MFL M8MQH0O9_%+1.W9)I_/\`#4^]_@C\<8?&_P"SOX8^.'Q%GT#PA!>Z3K.I^(KF M.::TT'2X=(\0:MHWG+)?W$LD<4Q4W5IH-E!+>W-E)C,9N+ MK3I2N"\*$[1]5E_`%62A/,L8J":3=*A'FG&_1U)6@I='RQG&^TFEKY]7-80D MHT8`]6TSS29;;1+G7_#]^(2. M%BO;V^U:(2*>G6X`R[DM0QF(HSMO/V=2-[K7E4:;U5_M=O.^$, MWJ*_/1COIRMQT?36_P!_7MU/TK_9S_:\^%W[1L,]AX?DN_#?C2PADN;_`,$Z M]);#4C:1&(2ZEH]S;N8M9TM7GC1Y(Q%-$Q'GV\2O&TGP^=<-X_(^6=2U?"2: M4:]--14G>T*D7K3F[-I.\9?9DVFEZF'Q=&NDH/EG_*]&OT>S\[*]K'U37SYU M!0!\T_M,_M+>%?V66 M`2R*&DD:6.&%2\A:/WLM>6.S=M_2U]3P7X)_LS^-?B!XHL_CW^UA?#Q5XTD2"^\%?#N8H_A7P M'9SJTT4=SHQC-L=2BW0%+=-\<4B--.]U=E98/8S7/L-@L/+)^'8?5L-&\:^( M2:JUI)_9GI+E>MY.TFGRQ4(74L*&'J3E&OB[2FM80Z03UU5OB6B\K;MZGW9X MN\*:-XV\*>(?!FOVPN=#\3:+J.A:G;@(K&RU.UEM)C"65A%.B2[XY`I*2(CC ME17R.&Q%7!XBABJ$N6KAYQJ0?]Z+4E?;1VLUU3:.Z45*,H->[)-->OD?S0_M M$?LE_$_]GG5;^75].EUSP&MWY>C^.].C7^SKF"8YMH]4MDD:71]1"D)(DJ^2 M74^3+(IX_<5V2G'JFM;-72=SYC$X*IAI;CEC*4&G%N+6UCZL\!?MU_M,_#^UATZU M^(-QXDTV!@R6?C*RL_$DI`&!$=6U")M3$/HBWJ@?PXKP<7PMD>,DYSP,:,WU MHN5%>O)!JG?_`+<.RGF&*IV7/S+LTG^.^VG;K:^I^A7P(_X*;^'?$]]IGAKX MT:!;>#M1O9EM1XPT)KB3PP)G7$3ZEIMP\UWI432`*9HY[M%,JEECC5G7X[-> M!*M"%2ME5:5>--7]A4LJMNJA.*C&3[1<8MI:-NR?HX?,X2:A5C[-WLFMM6DK M]M]7MI>VME]-?MZNC_LC_%MXV5T>U\&NCH0R,C?$'PD5964X92"""."#7A<( M)KB/+TU9KZPFGHTUAJQT9@T\%5:=T^2S7^.)_-+:&[6ZMOL!G6]\^(6GV9F2 MX^TEU$`@92"LQD*[2"#DCFOVZR?NNUGH[[?/R/F8I\RBM'>R^?H?NK\,?^"8 M?PJLO"6E2?$[5/$NN>,;JTBN=772=272=(TVYG7S386$$,#33"W#")YYYG\U MXVD5(E<1K^58[CK'/$3C@*5*EAHNT.>+E.2_FE[R2N[M))63LVWJ?04LJHQA M%5;RGULVEKV2[?CKY6_.7]LW]F:R_9J\?:+IV@:K>:KX0\8Z9=ZKX>;4_+.I MV$FF7$%MJNF7D\"1QW?DR7=G+'.L<1,=XJ,I:)I)/L^&<[EG6#JU*M.-+$86 M<85%&ZB^=.4)Q3UCS)23C=ZQ;NDTEYN.P?U2:<'^[EMW3ZI]^Z?R]?;_`/@E M_P"-=2TGXN>-_`JS/_8OBSX?:AK$]J3^[&L>%[ZQ6PN5&/E<6&M:M&2,;A(N M<[5QYG'.%ISRS#8NUJN%Q,(1>WN5HRYH]OBIP?R\V;Y3.4:E2%_<:V_O=+?) M2OWT/S5O/^/NZ_Z^9_\`T:U?:GDGZ!?M* M*>GOX;_TB9[&._W+"]-?_;6?!>D7.KQR76EZ+)=+/XCMHM`N+6S+";4K:YU+ M3KV/3<)\TB3:CI]@3&.',2J002#]5-4TE.:2C1;FG*UH-1E'GUT3492UZ)NQ MY5.4XWA3_P"7GNV76[T^=]NJ/U"^'W_!+#QQKNA6&K>._B'IO@O4;VT@N7\. MV.@OKUWIKSJ)/LU_?_VO:0?:HU8+(D"2HKA@LSJ`Q^%Q?'N"P]6=+"X.>)A" M32J>T5*,K:7C%TY2L]TW9V^RCU*>4S=-.4_9S=G:VU^CVU7D['@?[4WC76?` M>A^%OV0-(UZ34O"OP4DOT\1:S;P2:4GC#Q1K6I7WB1>];J<1:?I%KKD=FD M+S2AKN.YG/W81%Z^186CB:E;B.=%4\3FBBZ<&U/ZO1A&-*RERQ]^JZ;G*22] MQQBK7G?'&572A#!QEI05I/1*3WVN[6V[WOT9WG[$O[%FF?'ZQU3X@_$*^U"R M\`Z9J,NB:9IFD7"6FHZ_K%K':W%Z\]VT3M::1;PW4<9\D+---(P62);=O.Y. M)^)I9,Z>$P<(RQE6/.Y33Y*=-MJ+237-.33M?W8I:I\RM6`P,:Z=6H[4T[** M=F[+7;5:M?CW3/N3XA?\$RO@=JGA;58?A[_PD'A/Q9'8N^BWMQKVH:SIDNH0 M1$P0:I9ZI+.?LD[C;(UN\#J7W@G;L;Y3!\^HTXTY*+>KB MX):QOHFFK*VE[GH5LLH.#5)>RFOA?2][NZ[/;RZ=C\.O#VO>,/A%X^L]9TN: M\\.>,_`OB%@R+(T4UGJFCWC6]_IMWY+@36[R0SVMQ"2TFR MOOVZ^2N9WQE^+/AGX)?#S7_B%XID!LM'@"V>G)-'!=ZUJUQE-/T>P+AO])N) M1U"/Y<:2RLI2)JO+,NKYIC*6#PZUF_>E:ZIPNN:G*I M+11V6S;Z)>;/SJ_9`^&GB3]HOQ[J7[77QM9=45=5N+/X8Z!*)!IFGOIDDEM) MJ%M8O^Z_LS3W8VUFIW%KNWNKJ3,T<RO"^)FOB:G9\K MEOSU+,K+5W4(O9+HTNEM?7?U_6:OSL]4X#Q[\4_ MA[\+K?3KKQ_XKTOPK;ZM//;:;+J;S(MY/;1I+<1P^3"YW)'(C'('#"NS!Y?C M<>AP6F?M#?L]^/-1LO!^G?$'P MEXCO]?G73K/0V$T_]HSSA@MLL-S9B-V<`@!B,].]=D\FSG!0EB98.KAX4%S2 MG=+D2ZW4KHA5J$FH*I%MZ)777R.!^(O[#?[.'Q&E:\O/`EKX;U)@V=0\(RR> M'7=V))EN+73VCMKJ7<2=TT+GD^M=F"XKSK`I0CBG6IK[-9*>BTLG+WHKT:Z& M53`X:;NZ=GY-Q\ME9'P]\4?^"5TL$5UJ'PB\>23M%`TD/A[QA;Q>9<3*CL8H M=:TZ.)8%9@JJ);24\\MWKZG`M2BW9*__`#[E=OY37H<%7*4M M:,^5+I+\=5Y>6_4_(S7]`UGPIK>J^&_$.G7&D:YHE]<:;JFFW2A+BRO;60QS MP2A6925<'#*S*P(925()_0Z56G5I4ZU&:G2J14H26SC)737JCQI1E3DX27+* M+LUV9^H/A'XIZUX__P"":_QI\.Z_<&[O/AKJ_@_PWIUW([/(J35K1]K'#UXS&1E)!!X()!KZO-IRIY5F>=AE_M%!=/:05O)R2?WG]9M?SX?7GXZ?\%:(H_LGP-GV+YJW'Q`B#XPPC M:/P@Y3/]W./_0]$KW^-/\`D1/_`+"\-^54PRK^++^NDSX-O/\`C[NO^OF? M_P!&M7U9Y9^@7[2G_)G?[$_;_B3^./\`T=H]?)Y/IQ+Q3Y3PW_I$SV,=I@L+ MZ_\`MK/,OV$/"NE>+?VH_AG9:S;I=66ESZWXD2VE4-&]_P"']`U/5-)=E/!\ MG58+.X`/&;<5V<55ZF%R',)4I.$Y1A3NM+1JU80G]\)2C\SDR^$98JFI?9O) M>JU1_317X8?4'\H'[1MW/>?M`?&ZXN6+2GXL?$"/)SQ';^*M4MX%&>BK!%&H M'0!1CBOZ"R:*AE&5)*UL'AG;:S=&#:MWNW?S/DL4W]9KWTM4DODFTOP.Q^&/ MQ,_:E\+^$K72?A3J?Q+L_!T=W?S6D7AC2M4N=)^V3W+MJ#136EG)&TQNMXDP MQ(8$'!&*QQN!R.O7<\?1PLL1RQ3=64%/E2]W1R3M;;35%TJN*A!1I>T4([%-=,][J%],]Q>7<[ M"P&Z:6>1Y&/=G)[UZM/%9=0ITZ-+$X>G2HQ4(156FE&,4E&*][9))(YY4Z[D MY.G.[=_AEU^1_0-^P-'XALOV8?!&C^)=)U/1=0T/4?%FFQ6>K6%SIMY]B/B; M4[^WD:WNT23RS]N=$1HWAK MPVGC*[7:WX@N=0T^V>8`X*6FG:6X0D9!U*?UK[#@#`0A@\1CVOWF(K>P M5MXPIJ,FEYSE-7_P1.#-JCYZ=.UJ:UTTN^OW*UO.Y^R_PV\+Z9X)^'W@OPEH MT,,&F^'_``QHNEVJP*JQN+73X(Y+@[``TD\HDF=^KO*S')8U^98[$3Q6,Q6( MJ-\]:K4F[].:3=O1+1+HE8]FE%4Z=.$=%&*2MZ?J=M7*6?GO_P`%)_AMJ'C; MX`1Z_H]C->ZC\.O$UGXEN([=#).GA^XL[S2M;E6->3'!]JL;R4_PQ6$K?PU] MGP/C887-IT*DE"&-I.G&^B]K&49P7_;R4XI=92BCSLSI.6'YHJSI._\`VZU9 M[>=G\C\"O!'B[5_`'C#PQXWT!HH]9\)ZYIFOZ9YZ>9;M>:7=Q7<,=Q'QOMY& MBV2)_$CL.]?K6)P]+%8>OA:R?L:\)4YI:/EFG%V?1V=T^CU/GJ4W2J0J1WA) M.WH[V^9_1_\`"+]MKX%?$_P[9ZC=>+=-\&:_Y2KJOASQ)<"QN+.Z55$S6]RX M\FZLFD+>7*'5F7[R`U^+9CPKFV7UI0IX>6)HW]RI27-==+Q6L96W5K7ZGU%' M&4*D8VFHR_E>CO:[.T\7?M8?L_>"]'O-7U'XF>'+Q;2!YH['1[M=3U"\D524 MMK2"U#!IY"-JAW09/)%(;C4K*QD96EMK&.&"QLEG9`% M-RUI:0O*5`!D=R.#7[7EF$>7Y?@\$Y\[PU)0`=7\+?\$VOCWXJU6W-K'\0/$GA+4]$5QM>?0=(\9^ M"]+M[PCLDVHKJIC_`+T:(XX<5\MC,73J\;91A:;UP5*O&IY5*F'KS:^4/9W\ M[KH=\:3I977;7*ZC@_ESQMZ>GSZGQ%^SU_R7OX*?]E8^'G_J6Z37TF=?\B?- MO^P/%?\`IB9P8;_>/O\` MT1X2K](\/OCS+TI?G,\7./\`F'_[?_\`;3Y;_P"";'_)RA_[)IXX_P#0]$KZ M#C3_`)$3_P"PO#?E5,,J_BR_KI,^#;S_`(^[K_KYG_\`1K5]6>6?H%^TI_R9 MW^Q/_P!@?QQC_O\`:/7R>3_\E+Q3T?/AK?\`@$SV,=_N6%]?_;6.[^\L)H-`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`"OQ;`T#F,R1::]U; MR8SEX9;OP#_X)G^,-5U73=>^-US;^'_#D2K=2>%M-N1< M:WJ#AT:.TOIX_P!WI\!`<2J,R=-IY-?)9OQOA:,)T M3V:Z'H8?*Y74JSY(JSY5ONG9]M+W]3](?VJ?ACJ?B7]EWQQ\,/AEXWMPRK)DK';0R.0.?EK] M&S3B+)*^69A0HX^$JM;#5Z<(V:O.=*48KYMH\:A@L13K49.G)*$X-Z;)23?X M']$]?C!](?F?_P`%%_@A\3OC+9_">+X;^%[GQ&_A^Y\8OJRVTL47V)=1B\-K M9%_-89\TV=SC'_/(U]UP7F>`RV6/>-Q,<,JBI*'-?WK.=[6[:7]4>7F5"K5] MBJ4')1Y[VZ7Y;?>>`?L-?LQ?&[X5_',^*?'7@B]T#0?^$$\5Z4+^>:!X_M^H M-I1M(,1N3ND$$N#C^`U['%6>95C,H>'P>,C6K?6*$^2*:?+%5.9_*Z^\QR_# M5J%5N4'%=WITE_F?(5Q^P]^T_)<3R+\+]3VO-*Z_Z3:?=9V8?\M/0U]'_K/D M'_0QA]S.'ZAB?^?;^X^R?CG^S-\:_%/[,W[*_@?0?!-[>^)_`.F^+(/%>EI- M`LNE2:A+IAM%E9G"MY@@E(VD_=KYS+,[RJAGO$.*J8R-/#XJ5#V,VG::C&:E M9+LVCT<5AZL\+AZ<8-2@]4NFC1@_L3?LM_'/X8?M"^%?&'C?P+>Z%X=T_2O% M,%UJ,TUN\<,NH>'M0L[1"L;DYDN)HT&!U:M.)\]RG&Y+BL-A,9&K7G*ERP2: M>E6$I?@FS'`X2M0Q$9R@XQ2EJU;=,_<&ORD]T\'_`&A/V?O!G[1'@A_"7BE' MM+VRE>]\.>(+1$.H:%J3($::#<,26TR*J30-\LBJN>47'KY-G&)R7%*O0]ZG M+2I2;M&%A*G6%;W;75W:6 MS72_4\&IE^)I27+&ZULXO:VNO;]3S"+]G/\`:,UB:WL1\,_'UZ[2)'!%<6ER M\<9/R!@;B;9$H!QGC`->@\XRB"6XM%SF2 M/$A*BOB.(.,J\M?>[/34]+"9:Z4U4KV;CK&*V MOO=^A^P]?FQ[`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! &0`4`?__9 ` end EX-99.2 4 dp05247e_ex9902.htm Unassociated Document
 
EXHIBIT 99.02
 
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
       
 
Press Release
    

4 April 2007
 

Shire plc ("Shire")

Shire plc (the “Company”) - Shire Executive Annual Incentive Plan

On 2 April 2007 the trustee of the Shire plc Employee Benefit Trust (the “Trust”) informed the Company that, on 30 March 2007, the following Shares and ADSs had been allocated under the Shire Executive Annual Incentive Plan (the “Plan”) to the Executive Directors and Persons Discharging Managerial Responsibility set out below. The Ordinary Shares were bought on the market on 30 March 2007 at a price of £10.53 per share and the ADSs were bought on the same date at a price of USD62.1575 per ADS.

Name of Director
Type of Security
Number
Matthew Emmens
ADS
11,534
Angus Russell
Ordinary Shares
18,140

Name of PDMR
Type of Security
Number
Michael Cola
ADS
2,944
David Pendergast
ADS
3,123
Barbara Deptula
ADS
2,402
Eliseo Salinas
ADS
2,038
Anita Graham
ADS
2,072
John Lee
ADS
405
Tatjana May
Ordinary Shares
8,952
Joseph Rus
Ordinary Shares
6,492

Under the terms of the Plan the shares and ADSs will not normally be released to participants for three years.
 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252
 

Notes to editors

SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
Registered in England 2883758 Registered Office as above
 
EX-99.3 5 dp05247e_ex9903.htm Unassociated Document
EXHIBIT 99.03
 
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
       
 
Press Release
    


4 April 2007
 
Shire plc ("Shire")

 
Purchase of Shares by Employee Benefit Trust

 
Shire has been notified that on 3 April 2007, the Shire plc Employee Benefit Trust (the “Trust”) purchased 30,000 Ordinary Shares of Shire plc (“Shares”) at an average price of 1044.9634 pence per Share. The Trust also purchased 10,000 American Depositary Receipts of Shire plc (“ADR’s”) at an average price of 62.8336 dollars per ADR.

This/these purchase(s) was/were made pursuant to the Trustee’s irrevocable, non-discretionary programme to purchase Shares and ADR’s during the period commencing 02 April 2007 and ending on 30 April 2007.

All of the employees of Shire plc and its subsidiaries, including the Executive Directors and persons exercising managerial responsibility, are potential beneficiaries of the Trust. The Executive Directors and persons exercising managerial responsibility over Shire are therefore deemed to have an interest in the Shares held by the Trust.

 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252

Notes to editors

SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

 
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
 

Registered in England 2883758 Registered Office as above
 
 
 
 
 EX-99.4 6 dp05247e_ex9904.htm Unassociated Document
EXHIBIT 99.04
 
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
       
 
Press Release
    
 
5 April 2007
 
Shire plc ("Shire")

 
Purchase of Shares by Employee Benefit Trust

 
Shire has been notified that on 4 April 2007, the Shire plc Employee Benefit Trust (the “Trust”) purchased 30,000 Ordinary Shares of Shire plc (“Shares”) at an average price of 1047.4190 pence per Share. The Trust also purchased 10,000 American Depositary Receipts of Shire plc (“ADR’s”) at an average price of 62.6780 dollars per ADR.

This/these purchase(s) was/were made pursuant to the Trustee’s irrevocable, non-discretionary programme to purchase Shares and ADR’s during the period commencing 02 April 2007 and ending on 30 April 2007.

All of the employees of Shire plc and its subsidiaries, including the Executive Directors and persons exercising managerial responsibility, are potential beneficiaries of the Trust.  The Executive Directors and persons exercising managerial responsibility over Shire are therefore deemed to have an interest in the Shares held by the Trust.
 
 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252

 
Notes to editors

SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
 
 
Registered in England 2883758 Registered Office as above

 
 
 
 
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.
 

Registered in England 2883758 Registered Office as above
 
 
 
 
 EX-99.5 7 dp05247e_ex9905.htm Unassociated Document
EXHIBIT 99.05
 
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
       
 
Press Release
    
 

5 April 2007


Shire plc (the “Company”)

The trustee of the Shire plc Employee Benefit Trust (the “Trust”) notified the Company on 4 April 2007 that, on that day it exercised its discretion and released a total of 1,953 ordinary shares in the Company for nil consideration, being the release of shares to a beneficiary of the Trust on satisfaction of an award under the Shire 2003 Deferred Bonus Plan.

None of the shares released were in respect of an award made to a director of the Company.

Following these transactions the trustee holds a total of 56,023,738 ordinary shares in the Company. The executive directors of the Company are amongst the potential beneficiaries under the Trust and are therefore regarded for Companies Act purposes as being interested in the shares held in them pursuant to DR 3.1.4R(1)(6).


Tatjana May
Company Secretary
 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
     
 
Eric Rojas (North America)
+1 484 595 8252

Notes to editors

SHIRE PLC
 
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
 
For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
Registered in England 2883758 Registered Office as above

 
 
 -----END PRIVACY-ENHANCED MESSAGE-----